TM-38837

TM-38837

Systematic (IUPAC) name
1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
Clinical data
Legal status	?
Identifiers
ATC code	none
PubChem	CID 49779607
ChemSpider	29361353
Chemical data
Formula	C30H25Cl2F3N4OS
Molar mass	617.51 g/mol
SMILES O=C(C1=NN(C2=CC=C(Cl)C=C2Cl)C(C3=CC=C(C#CC4=CC=C(C(F)(F)F)C=C4)S3)=C1CC)NN5CCCCC5
InChI InChI=1S/C30H25Cl2F3N4OS/c1-2-23-27(29(40)37-38-16-4-3-5-17-38)36-39(25-14-11-21(31)18-24(25)32)28(23)26-15-13-22(41-26)12-8-19-6-9-20(10-7-19)30(33,34)35/h6-7,9-11,13-15,18H,2-5,16-17H2,1H3,(H,37,40) Key:VQOCBFYUDSBDCZ-UHFFFAOYSA-N

TM-38837 is a small molecule inverse agonist/antagonist of the CB₁ cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.^[1] The company has announced phase I clinical trials.

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB₁ receptor antagonists such as rimonabant.^[2]

See also

• AM-6545

References

1. http://web.archive.org/web/20110707065905/http://www.7tm.com/. Archived from the original on July 7, 2011. Retrieved January 18, 2011. Missing or empty |title= (help)
2. Hung, M. S.; Chang, C. P.; Li, T. C.; Yeh, T. K.; Song, J. S.; Lin, Y.; Wu, C. H.; Kuo, P. C.; Amancha, P. K.; Wong, Y. C.; Hsiao, W. C.; Chao, Y. S.; Shia, K. S. (2010). "Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist". ChemMedChem 5 (9): 1439–1443. doi:10.1002/cmdc.201000246. PMID 20652930.

External links

• Experimental obesity drug avoids brain effects that troubled predecessors, press release